Issue 65, 2022

Rationally designed Ru(ii) metallacycles with tunable imidazole ligands for synergistical chemo-phototherapy of cancer

Abstract

Herein, we construct a series of Ru(II) metallacycles with multimodal chemo-phototherapeutic properties, which exhibited much higher anticancer activity and better cancer-cell selectivity than cisplatin. The antitumor mechanism could be ascribed to the activation of caspase 3/7 and the resulting apoptosis. These results open new possibilities for Ru(II) metallacycles in biomedicine.

Graphical abstract: Rationally designed Ru(ii) metallacycles with tunable imidazole ligands for synergistical chemo-phototherapy of cancer

Supplementary files

Article information

Article type
Communication
Submitted
02 jun. 2022
Accepted
19 jul. 2022
First published
20 jul. 2022

Chem. Commun., 2022,58, 9068-9071

Rationally designed Ru(II) metallacycles with tunable imidazole ligands for synergistical chemo-phototherapy of cancer

L. Tu, C. Li, C. Liu, S. Bai, J. Yang, X. Zhang, L. Xu, X. Xiong and Y. Sun, Chem. Commun., 2022, 58, 9068 DOI: 10.1039/D2CC03118C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements